114 related articles for article (PubMed ID: 38432130)
1. Everolimus decreases [U-
Ariaans G; Tiersma JF; Evers B; Gerding A; Waaijer SJH; Koster RA; Touw DJ; Bakker BM; Reijngoud DJ; de Jong S; Jalving M
Biomed Pharmacother; 2024 Apr; 173():116362. PubMed ID: 38432130
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor effects of everolimus and metformin are complementary and glucose-dependent in breast cancer cells.
Ariaans G; Jalving M; Vries EG; Jong S
BMC Cancer; 2017 Mar; 17(1):232. PubMed ID: 28356082
[TBL] [Abstract][Full Text] [Related]
3. Combined Use of Metformin and Everolimus Is Synergistic in the Treatment of Breast Cancer Cells.
Wang Y; Wei J; Li L; Fan C; Sun Y
Oncol Res; 2014; 22(4):193-201. PubMed ID: 26351208
[TBL] [Abstract][Full Text] [Related]
4. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
5. High Glucose Represses the Anti-Proliferative and Pro-Apoptotic Effect of Metformin in Triple Negative Breast Cancer Cells.
Varghese S; Samuel SM; Varghese E; Kubatka P; Büsselberg D
Biomolecules; 2019 Jan; 9(1):. PubMed ID: 30626087
[TBL] [Abstract][Full Text] [Related]
6. Metabolic heterogeneity in TNBCs: A potential determinant of therapeutic efficacy of 2-deoxyglucose and metformin combinatory therapy.
Samuel SM; Varghese E; Satheesh NJ; Triggle CR; Büsselberg D
Biomed Pharmacother; 2023 Aug; 164():114911. PubMed ID: 37224753
[TBL] [Abstract][Full Text] [Related]
7. Pyruvate carboxylase supports the pulmonary tropism of metastatic breast cancer.
Shinde A; Wilmanski T; Chen H; Teegarden D; Wendt MK
Breast Cancer Res; 2018 Jul; 20(1):76. PubMed ID: 30005601
[TBL] [Abstract][Full Text] [Related]
8. Effect of metformin on estrogen and progesterone receptor-positive (MCF-7) and triple-negative (MDA-MB-231) breast cancer cells.
Amaral I; Silva C; Correia-Branco A; Martel F
Biomed Pharmacother; 2018 Jun; 102():94-101. PubMed ID: 29550639
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of everolimus in combination with paclitaxel on adriamycin-resistant breast cancer cell line MDA-MB-231.
Xu T; Liu P; Li Q; Shi C; Wang X
Taiwan J Obstet Gynecol; 2020 Nov; 59(6):828-834. PubMed ID: 33218396
[TBL] [Abstract][Full Text] [Related]
10. Synergic Effect of Metformin and Everolimus on Mitochondrial Dynamics of Renal Cell Carcinoma.
Hong SH; Lee KS; Hwang HJ; Park SY; Han WK; Yoon YE
Genes (Basel); 2022 Jul; 13(7):. PubMed ID: 35885994
[TBL] [Abstract][Full Text] [Related]
11. Mass spectrometry analysis shows the biosynthetic pathways supported by pyruvate carboxylase in highly invasive breast cancer cells.
Phannasil P; Ansari IH; El Azzouny M; Longacre MJ; Rattanapornsompong K; Burant CF; MacDonald MJ; Jitrapakdee S
Biochim Biophys Acta Mol Basis Dis; 2017 Feb; 1863(2):537-551. PubMed ID: 27890529
[TBL] [Abstract][Full Text] [Related]
12. Co-treatment of breast cancer cells with pharmacologic doses of 2-deoxy-D-glucose and metformin: Starving tumors.
Wokoun U; Hellriegel M; Emons G; Gründker C
Oncol Rep; 2017 Apr; 37(4):2418-2424. PubMed ID: 28350075
[TBL] [Abstract][Full Text] [Related]
13. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
[TBL] [Abstract][Full Text] [Related]
14. The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.
Emberley E; Pan A; Chen J; Dang R; Gross M; Huang T; Li W; MacKinnon A; Singh D; Sotirovska N; Steggerda SM; Wang T; Parlati F
PLoS One; 2021; 16(11):e0259241. PubMed ID: 34731180
[TBL] [Abstract][Full Text] [Related]
15. Glucose promotes breast cancer aggression and reduces metformin efficacy.
Wahdan-Alaswad R; Fan Z; Edgerton SM; Liu B; Deng XS; Arnadottir SS; Richer JK; Anderson SM; Thor AD
Cell Cycle; 2013 Dec; 12(24):3759-69. PubMed ID: 24107633
[TBL] [Abstract][Full Text] [Related]
16. Metformin induces unique biological and molecular responses in triple negative breast cancer cells.
Liu B; Fan Z; Edgerton SM; Deng XS; Alimova IN; Lind SE; Thor AD
Cell Cycle; 2009 Jul; 8(13):2031-40. PubMed ID: 19440038
[TBL] [Abstract][Full Text] [Related]
17. Metabolic characterization of aggressive breast cancer cells exhibiting invasive phenotype: impact of non-cytotoxic doses of 2-DG on diminishing invasiveness.
Fujita M; Imadome K; Somasundaram V; Kawanishi M; Karasawa K; Wink DA
BMC Cancer; 2020 Sep; 20(1):929. PubMed ID: 32993545
[TBL] [Abstract][Full Text] [Related]
18. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
[TBL] [Abstract][Full Text] [Related]
19. Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer.
Gordon MA; D'Amato NC; Gu H; Babbs B; Wulfkuhle J; Petricoin EF; Gallagher I; Dong T; Torkko K; Liu B; Elias A; Richer JK
Mol Cancer Ther; 2017 Jul; 16(7):1389-1400. PubMed ID: 28468774
[TBL] [Abstract][Full Text] [Related]
20. The anti-proliferative effect of metformin in triple-negative MDA-MB-231 breast cancer cells is highly dependent on glucose concentration: implications for cancer therapy and prevention.
Zordoky BN; Bark D; Soltys CL; Sung MM; Dyck JR
Biochim Biophys Acta; 2014 Jun; 1840(6):1943-57. PubMed ID: 24462945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
